Strategies targeting immune checkpoints are also entering late clinical testing in hematology (i.e., TIM-3 mAb in MDS/AML) or are already approved (PD-1 blocker in cHL). The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.